Disclosure of a putative biosignature for respiratory chain disorders through a metabolomics approach

Metabolomics

Volumn 9, Issue 2, 2013, Pages 379-391

  Smuts, Izelle ^a   van der Westhuizen, Francois H ^b   Louw, Roan ^b   Mienie, Lodewyk J ^b   Engelke, Udo F H ^c   Wevers, Ron A ^c   Mason, Shayne ^b   Koekemoer, Gerhard ^b   Reinecke, Carolus J ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biosignature; Data reduction; Metabolomics; Respiratory chain disorders; Urinary amino acids; Urinary organic acids

Indexed keywords

2 AMINOADIPIC ACID; 2 HYDROXYGLUTARIC ACID; 3 HYDROXY 2 METHYLPROPIONIC ACID; 3 HYDROXY 3 METHYLGLUTARIC ACID; 3 HYDROXYISOVALERIC; ACYLCARNITINE; ALANINE; AMINO ACID; BETAINE; BIOLOGICAL MARKER; CARBOXYLIC ACID; CARNITINE; CREATINE; GLUTAMIC ACID; GLYCINE; LACTIC ACID; SERINE; SUCCINIC ACID; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLOME; METABOLOMICS; MUSCLE BIOPSY; MUSCLE DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; RESPIRATORY CHAIN; RESPIRATORY CHAIN DISORDER; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; URINALYSIS; URINE LEVEL; VALIDATION PROCESS;

EID: 84875522332     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-012-0455-z     Document Type: Article

References (40)

1. Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., et al. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics, 69(3), 89-95.
2. Barker, M., & Rayens, W. (2003). Partial least squares for discrimination. Journal of Chemometrics, 17(3), 166-173.
3. Bijlsma, S., Bobeldijk, I., Verheij, E. R., Ramaker, R., Kochhar, S., Macdonald, I. A., et al. (2006). Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation. Analytical Chemistry, 78(2), 567-574.
4. Brereton, R. G. (2003). Chemometrics-data analysis for the laboratory and chemical plant. Chichester: John Wiley & Sons Ltd.
5. Calvo, S. E., & Mootha, V. K. (2010). The mitochondrial proteome and human disease. Annual Review of Genomics and Human Genetics, 11, 25-44.
6. Chong, I. G., & Jun, C. H. (2005). Performance of some variable selection methods when multicollinearity is present. Chemometrics and Intelligent Laboratory Systems, 78(1-2), 103-112.
7. Chung, Y., Rider, L., Bell, J., Summers, R. M., Zemel, L. S., Rennebohm, R. M., et al. (2005). Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Care & Research, 53(4), 565-570.
8. Ellis, S., & Steyn, H. (2003). Practical significance (effect sizes) versus or in combination with statistical significance (p-values). Management Dynamics, 12(4), 51-53.
9. Elstner, M., & Turnbull, D. M. (2011). Transcriptome analysis in mitochondrial disease. Brain Research Bulletin,. doi: 10. 1016/j. brainresbull. 2011. 07. 018.
10. Engelke, U. F. H., Liebrand-van Sambeek, M. L. F., de Jong, J. G., Leroy, J. G., Morava, E., Smeitink, J. A., et al. (2004). N-acetylated metabolites in urine: Proton nuclear magnetic resonance spectroscopic study on patients with inborn errors of metabolism. Clinical Chemistry, 50(1), 58-66.
11. 1H-NMR spectroscopy in inborn errors of metabolism: body fluid NMR spectrum and in vivo MR spectroscopy. Amsterdam: SPS Publications.
12. Ferrara, C. T., Wang, P., Neto, E. C., Stevens, R. D., Bain, J. R., Wenner, B. R., et al. (2008). Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genetics, 4(3), e1000034.
13. Fluss, R., Faraggi, D., & Reiser, B. (2005). Estimation of the youden index and its associated cutoff point. Biometrical Journal, 47(4), 458-472.
14. Frankenhaeuser, M., Lundberg, U., Von Wright, M. R., Von Wright, J., & Sedvall, G. (1986). Urinary monoamine metabolites as indices of mental stress in healthy males and females. Pharmacology Biochemistry and Behaviour, 24(6), 1521-1525.
15. Giak-Sim, K., Carpenter, K., Hammond, J., Christodoulou, J., & Wilcken, B. (2002). Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid [beta]-oxidation defects: Phenotype/metabolite correlations. Molecular Genetics and Metabolism, 76(4), 327-334.
16. Haas, R. H., Parikh, S., Falk, M. J., Saneto, R. P., Wolf, N. I., Darin, N., et al. (2008). The in-depth evaluation of suspected mitochondrial disease. Molecular Genetics and Metabolism, 94(1), 16-37.
17. Hu, F. B. (2011). Metabolic profiling of diabetes: From black-box epidemiology to systems epidemiology. Clinical Chemistry, 57(9), 1224-1226.
18. Jacobsen, M., Mattow, J., Repsilber, D., & Kaufmann, S. H. E. (2008). Novel strategies to identify biomarkers in tuberculosis. Biological Chemistry, 389(5), 487-495.
19. Johnson, R. A., & Wichern, D. W. (1998). Applied multivariate statistical analysis (4th ed.). Englewood Cliffs, NJ: Prentice-Hall Inc.
20. Kell, D. B. (2004). Metabolomics and systems biology: making sense of the soup. Current Opinion in Microbiology, 7(3), 296-307.
21. Koene, S., & Smeitink, J. (2011). Mitochondrial medicine. Journal of Inherited Metabolic Disease, 34(2), 247-248.
22. Levine, R. J., & Conn, H. O. (1967). Tyrosine metabolism in patients with liver disease. Journal of Clinical Investigation, 46(12), 2012-2020.
23. Mancuso, M., Orsucci, D., Coppedè, F., Nesti, C., Choub, A., & Siciliano, G. (2009). Diagnostic approach to mitochondrial disorders: The need for a reliable biomarker. Current Molecular Medicine, 9(9), 1095-1107.
24. Martín-Hernández, E., García-Silva, M. T., Vara, J., Campos, Y., Cabello, A., Muley, R., et al. (2005). Renal pathology in children with mitochondrial diseases. Pediatric Nephrology, 20(9), 1299-1305.
25. Mels, C. M. C., van Rensburg, P. J., van der Westhuizen, F. H., Pretorius, P. J., & Erasmus, E. (2011). Increased excretion of C4-carnitine species after a therapeutic acetylsalicylic acid dose: Evidence for an inhibitory effect on short-chain fatty acid metabolism. ISRN Pharmacology,. doi: 10. 5402/2011/851870.
26. Morath, M., Okun, J., Müller, I., Sauer, S. W., Hörster, F., Hoffmann, G. F., et al. (2008). Neurodegeneration and chronic renal failure in methylmalonic aciduria-A pathophysiological approach. Journal of Inherited Metabolic Disease, 31(1), 35-43.
27. Odièvre, M., Lombes, A., Dessemme, P., Santer, R., Brivet, M., Chevallier, B., et al. (2002). A secondary respiratory chain defect in a patient with Fanconi-Bickel syndrome. Journal of Inherited Metabolic Disease, 25(5), 379-384.
28. Rauste-von Wright, M., & Frankenhaeuser, M. (1989). Females' emotionality as reflected in the excretion of the dopamine metabolite HVA during mental stress. Psychological Reports, 64(3), 856-858.
29. Reinecke, F., Smeitink, J. A. M., & van der Westhuizen, F. H. (2009). OXPHOS gene expression and control in mitochondrial disorders. Biochimicaet Biophysica Acta (BBA)-Molecular Basis of Disease, 1792(12), 1113-1121.
30. Reinecke, C. J., Koekemoer, G., van der Westhuizen, F. H., Louw, R., Lindeque, J. Z., Mienie, L. J., et al. (2012). Metabolomics of urinary organic acids in respiratory chain deficiencies in children. Metabolomics, 8(2), 264-283.
31. Shaham, O., Slate, N. G., Goldberger, O., Xu, Q., Ramanathan, A., Souza, A. L., et al. (2010). A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proceedings of the National Academy of Sciences of the USA, 107(4), 1571-1575.
32. Smuts, I., Louw, R., Du Toit, H., Klopper, B., Mienie, L. J., & van der Westhuizen, F. H. (2010). An overview of a cohort of South African patients with mitochondrial disorders. Journal of Inherited Metabolic Disease,. doi: 10. 1007/s10545-009-9031-8.
33. Suomalainen, A. (2011). Biomarkers for mitochondrial respiratory chain disorders. Journal of Inherited Metabolic Disease, 34(2), 1-6.
34. Suomalainen, A., Elo, J. M., Pietiläinen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M., et al. (2011). FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: A diagnostic study. The Lancet Neurology, 10(9), 806-818.
35. Sztajnkrycer, M. D. (2002). Valproic acid toxicity: Overview and management. Clinical Toxicology, 40(6), 789-801.
36. Thorburn, D. (2004). Mitochondrial disorders: Prevalence, myths and advances. Journal of Inherited Metabolic Disease, 27(3), 349-362.
37. Turnbull, D. (2011). A new biomarker for mitochondrial disease. The Lancet Neurology, 10(9), 777-778.
38. Wikoff, W. R., Pendyala, G., Siuzdak, G., & Fox, H. S. (2008). Journal of Clinical Investigation, 118(7), 2661-2669.
39. Wolf, N. I., & Smeitink, J. A. M. (2002). Mitochondrial disorders. Neurology, 59(9), 1402-1405.
40. Wong, L. J. C., Scaglia, F., Graham, B. H., & Craigen, W. J. (2010). Current molecular diagnostic algorithm for mitochondrial disorders. Molecular Genetics and Metabolism, 100(2), 111-117.